Treatment for Post Acute COVID-19 Syndrome

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Post-acute COVID-19 tinnitus has not been treated successfully. As tinnitus may be related to SARS-CoV-2 neurological manifestations. This study aims to investigate if the dopamine receptor antagonists can be used effectively treat COVID-19 induced tinnitus.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Applied Biology, Inc.
• Collaborator: Jupiter Wellness, Inc.
• Treatments: Pimozide

Criteria

Inclusion Criteria:

1. Diagnosed with subjective tinnitus post COVID-19

2. Tinnitus persists for at least 4 weeks

3. Prior history of mild or no tinnitus

4. 18 years or older

5. Any gender

6. Females of child bearing age must be on contraception

Exclusion Criteria:

1. Pregnant

2. Patients who participated in any interventional studies in the past 6 months

3. Patients with severe hepatic impairment on admission (alanine aminotransferase higher than fivefold the upper limit)

4. Patients taking any dopamine receptor antagonists

5. Patient having history of hypersensitivity to Pimozide

6. Patients unable to comply with the study schedule

7. Actively using cortiocosteroids